kimi aoki therapy inc.

75-38 113th street, 1f
forest hills, new york, 11375

NYS Entity Status
ACTIVE

NYS Filing Date
JUNE 27, 2013

NYS DOS ID#
4423766

County
QUEENS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - KIMI AOKI THERAPY INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Listing of the Day: Toronto Forest Hill
    Friday Jun 23, 2017

    The sprawling steel-frame and concrete mansion sits in Toronto's most prestigious and affluent neighborhoods.

    Source: The Wall Street Journal: Most Popular
  • Neighborhood Joint: Staubitz Market in Brooklyn: 100 Years of Sawdust, Steaks and Chops
    By ANDREW COTTO - Wednesday Jun 14, 2017

    A display contains frozen items, and the shelves are stocked with jars and cans. But there’s just one reason to visit this Boerum Hill business: meat.

    Source: NYT > Home Page
  • Neighborhoods That Play Hard to Get
    By STEFANOS CHEN - Friday Aug 11, 2017

    In some New York neighborhoods, the housing stock is great, but turnover is so low, word of mouth is the best search engine.

    Source: NYT > Home Page
  • A New Way for Therapists to Get Inside Heads: Virtual Reality
    By CADE METZ - Sunday Jul 30, 2017

    Limbix, a start-up using Google headsets, helps psychologists expose patients to their anxieties in the safety of an office.

    Source: NYT > Home Page
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York